Is there a path for approval of an antiobesity drug: What did the Sibutramine Cardiovascular Outcomes Trial find?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 5, 2011, Pages 321-327

  Downey, Morgan ^a   Still, Christopher ^b   Sharma, Arya M ^c  

^a Downey Obesity Report   (United States)

^b Geisinger Obesity Institute   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Food and Drug Administration approval; obesity; weight loss medications

Indexed keywords

ANTIOBESITY AGENT; SIBUTRAMINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG APPROVAL; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; OBESITY; REVIEW;

ADVISORY COMMITTEES; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CYCLOBUTANES; DRUG APPROVAL; HUMANS; OBESITY; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80052487982     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32834a8726     Document Type: Review

References (29)

1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional and global trends in body mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377:557-567.
2. Williams G. Withdrawal of sibutramine in Europe. BMJ 2010; 340:824.
3. Heal DJ, Frankland AT, Gosden J, et al. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminer-gic function: evidence that dompanine is not a pharmacological target for sibutramine. Psychopharmacology (Berl) 1992; 107:303-309.
4. Bello NT, Liang NC. The use of serotonergic drugs to treat obesity: is there any hope? Drug Design Dev Ther 2011; 5:95-109.
5. Jordan J, Schlaich M, Redon J, et al. European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes. J Hypertens 2011; 29:189-193.
6. Rucker D, Padwal R, Li SK, et al. Longtermpharmacotherapyforobesityand overweight: updated meta-analysis. BMJ 2007; 335:1194-1199.
7. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modificationand pharmacotherapyforobesity. N Engl JMed 2005;353:2111-2120. (Pubitemid 41653103)
8. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21:457-466.
9. Andersson C, Weeke P, Brendorp B, et al. Differential changes in serum aric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutr Metab 2009; 6:42.
10. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2008; 9:378-387. (Pubitemid 351842191)
11. Torp-Pedersen C, Caterson I, Coutinho W, et al. Cardiovascular responsesto weight management and sibutramine in high-risk subjects: an analysis from the SCOUT Trial. Eur Heart J 2007; 28:2915-2923. (Pubitemid 350233016)
12. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardio-vascular outcomes in overweight obese subjects. N Engl J Med 2010; 363:905-917.
13. Harrison-Woolrych M, Ashton J, Herbison P. Fatal and non-fatal cardiovas-cular events in a general population prescribed sibutramine in New Zealand. A prospective cohort study. Drug Saf 2010; 33:605-613.
14. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release phentermine plus topiramate combination on weight and associated cormor-biditiesinoverweightand obeseadults (CONQUER):arandomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:1341-1352.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352:854-865.
16. Dorner TE, Rieder A. Obesity paradox in elderly patientswith cardiovascular disease. Int J Cardiol 2011. [Epub ahead of print]
17. Fox KAA, Despres JP, Richard AJ, et al. Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91, 246 ambulant patient in 27 European Countries. Eur Heart J 2009; 30: 3055-3063.
18. Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardio-vascular events (CREASCENDO): a randomized, multicentre, placebo-con-trolled trial. Lancet 2010; 376:517-523.
19. Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co-medica-tion among users of antiobesity drugs: a population-based study. Pharm World Sci 2010; 32:752-758.
20. Kortelainen ML, Porvari K. Extreme obesity and associated cardiovascular disease verified at autopsy: time trends over 3 decades. Am J Forensic Med Pathol 2011. doi: 10.1097/PAF.0b013e318219cd89. [Epub ahead of print]
21. He M, Cornelis C, Frank PW, et al. Obesity genotype score and cardiovas-cular risk in women with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2010; 30:327-332.
22. Hofso D, Nordstrand N, Johnson LK, et al. Obesity-related cardiovascular risk factors afterweight loss: aclinical trial comparing gastric bypass surgeryand intensive lifestyle intervention. Eur J Endocrinol 2010; 163:735-745.
23. Adan RA, Vanderschuren LJ, la Fleur SE.Antiobesitydrugsand neural circuits of feeding. Trends Pharmacol Sci 2008; 4:208-217.
24. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008; 359:1092-1095.
25. Goldfine AD, Beckman JA. Life and death in Denmark: lessons aboutdiabetes and coronary heart disease. Circulation 2008; 117:1914-1917. (Pubitemid 351543466)
26. Curfman GD, Morrissey S, Drazen JM. Sibutramine: another flawed diet pill. N Engl J Med 2010; 363:972-974.
27. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the US Food and Drug Administration. N Eng J Med 2010; 363:1489-1491.
28. Dvorak RV, Sharma AM, Astrup A. Antiobesity drugs: to be or not to be? Obes Rev 2010; 11:833-834.
29. Wright SM, Aronne LJ. Obesity in 2010: the future of obesity medicine -where do we go from here? Nat Rev Endocrinol 2011; 7:69-70.